@article{TCR8530,
author = {Frederick L. Locke and Marco L. Davila},
title = {Chimeric antigen receptor T cells get passed by leukemia},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 2},
year = {2016},
keywords = {},
abstract = {New immunotherapy treatments have led to dramatic responses in patients with chemotherapy-refractory solid tumors, leukemias, and lymphomas. One of these immunotherapies involves the adoptive transfer of autologous T cells gene-engineered to express a chimeric antigen receptor (CAR) that is a hybrid of an antibody and a T cell receptor (TCR) (1). The antibody portion provides new antigen specificity and after binding, the intracellular TCR domains of the CAR induce T cell activation and tumor killing. CAR T cells targeted against CD19, a protein expressed on nearly all normal and cancerous B cells, has mediated impressive responses in patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). Four groups have reported complete remission (CR) rates up to 90% in pediatric and/or adult patients with B-ALL, while the expected CR rate with chemotherapy alone is },
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/8530}
}